RPAM
BIVV

Rhenman & Partners Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-35,000
Closed -$2M – 103
2017
Q3 		$2M Buy
35,000
+4,000
+13% +$234K 0.25% 76
2017
Q2 		$1.86M Hold
31,000
– – 0.27% 79
2017
Q1 		$1.69M Buy
+31,000
New +$1.53M 0.27% 79

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Rhenman & Partners Asset Management's BIVV Position: Q4 2017 in Review

Rhenman & Partners Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 35,000 shares — an estimated $2M sold.

Rhenman & Partners Asset Management first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $2M in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Rhenman & Partners Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 35,000 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $2M.
  • Rhenman & Partners Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Rhenman & Partners Asset Management's Bioverativ Inc. Common Stock position peaked at $2M in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.